查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1933335

治療性白蛋白市場

Therapeutic Albumin Market
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 186 Pages | 商品交期: 請詢問到貨日

價格

治療性白蛋白市場成長因子

由於慢性疾病、創傷和燒傷病例的增加，全球治療性白蛋白市場正經歷穩定成長。治療性白蛋白是一種主要從人類血漿中純化的蛋白質。它在維持膠體滲透壓、運輸激素、酵素和藥物以及治療低血容量、燒傷、低白蛋白血症、急性肝衰竭和休息方面發揮著重要作用。重組白蛋白生產技術的進步以及在再生醫學和細胞療法領域應用的拓展，正在推動市場進一步成長。

預計2025年市場規模將達72.3億美元，2026年成長至77億美元，到2034年將達到133.3億美元。預計2026年至2034年期間的複合年增長率（CAGR）為7.10%。亞太地區將在2025年佔市場主導地位，市佔率將達到55.49%，主要得益於該地區慢性病和燒傷的高發生率。

市場驅動因素與趨勢

慢性病負擔加重和燒傷病例增加

肝病、腎臟病和癌症盛行率的上升，以及燒傷病例的增加，正在推動市場成長。例如，在美國，2024年將有600萬確診腎病患者和450萬確診慢性肝病患者，2023年將有32,540例嚴重燒傷病例需要住院治療。這表明，在液體復甦和重症監護環境中，對治療性白蛋白的需求量很大。

白蛋白生產技術的進步

由於人源白蛋白存在供應短缺、病原體傳播風險和批次間差異等局限性，各公司正在投資重組白蛋白和先進的白蛋白製劑。像Silpa Medicare的sRbumin（一種酵母來源的重組白蛋白）這樣的創新技術正在彌補供應缺口，並提高安全性和穩定性。

再生醫學的新應用

治療性白蛋白的生物相容性和蛋白質穩定特性使其成為細胞治療和組織工程的理想選擇，為市場成長提供了新的機會。 Albumedix 和 Heartseed 等公司進行的合作研究計畫正在探索重組白蛋白在心臟細胞治療中的應用，從而拓展其臨床應用範圍。

市場挑戰

監管障礙、高昂的生產成本和有限的人血漿供應仍然是主要挑戰。 FDA、EMA 和 NMPA 的審批流程延緩了產品上市，發展中國家的供應和價格仍然是難題。供應鏈中斷，例如美國紅十字會預測的 2024 年美國血液短缺，進一步限制了市場成長。

市場區隔

依原料

  • 預計到 2026 年，人源白蛋白將佔 65.17% 的市場佔有率，主要受慢性疾病的普遍流行以及 Grifols、Octapharma 和 Kedrion 等公司強大的產品供應推動。
  • 為了克服供應限制，其他原料，包括重組白蛋白和植物源白蛋白，正受到越來越多的關注。

依適應症

  • 預計到 2026 年，燒傷護理將佔 89.66% 的市場佔有率，其主要目的是控制燒傷患者的體液流失。
  • 由過度出汗、腹瀉或慢性心臟病和腎臟病等引起的低血容量的發生率正在穩步上升。
  • 低白蛋白血症和其他適應症呈現溫和成長趨勢。

依通路劃分

  • 由於住院治療和外科手術的需求，醫院藥局佔市場主導地位（預計2026年市佔率為54.56%）。
  • 零售藥局提供廣泛的藥品供應。
  • 由於數位化程度的提高和送貨上門的便利性，線上藥局正在快速成長。

區域洞察

預計亞太地區將在2025年以40.1億美元的市場規模引領市場，其次是日本（8.5億美元）、中國（18.6億美元）和印度（4.6億美元），預計2026年這一數字將由慢性病和燒傷病例的普遍存在所驅動。

北美市場正經歷穩定成長，預計到2026年，美國市場規模將達到15.2億美元，這得益於其強大的血漿捐贈網路和先進的生產設施。

歐洲是第二大市場，預計到2026年，英國和德國的市場規模將分別達到1.8億美元和2.8億美元，主要得益於臨床試驗和研究活動的發展。

拉丁美洲和中東/非洲的市場規模較小，但由於慢性病盛行率的上升和血漿採集活動的擴大，預計這些地區的市場也將成長。

目錄

第一章：引言

第二章：摘要整理

第三章：市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第四章：關鍵考慮因素

  • 主要國家和地區主要疾病流行情況（2025 年）
  • 概述：rHSA 產品參數
  • 主要公司新產品發布
  • 主要公司產品線分析
  • 主要產業趨勢：併購、業務合作等
  • COVID-19 對全球的影響治療性白蛋白市場

第五章 全球治療性白蛋白市場分析：洞察與預測（2021-2034）

  • 市場分析、洞察與預測：依來源
    • 人源性
    • 其他
  • 市場分析、洞察與預測：依適應症
    • 低血容
    • 低白蛋白血症
    • 燒傷
    • 其他
  • 市場分析、洞察與預測：依分銷管道
    • 醫院藥房
    • 零售藥房
    • 線上藥房
  • 市場分析、洞察與預測：依地區
    • 北美美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第六章 北美治療性白蛋白市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 美國
    • 加拿大

第七章 歐洲治療性白蛋白市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 斯堪的納維亞
    • 歐洲其他地區

第八章 亞太地區治療性白蛋白市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 中國
    • 日本
    • 印度
    • 澳大利亞
    • 東南亞
    • 亞太其他地區

第九章：拉丁美洲治療性白蛋白市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地區

    第十章：中東與非洲治療性白蛋白市場分析：洞察與預測（2021-2034）

    • 依國家劃分
      • 海灣地區海灣合作委員會 (GCC) 國家
      • 南非
      • 其他中東和非洲國家

    第十一章 競爭分析

    • 全球市佔率分析（2025 年）
    • 公司簡介
    • Takeda Pharmaceutical Company Limited.
    • CSL
    • Grifols, S.A.
    • Octapharma AG
    • Kedrion S.p.A.
    • Biotest AG
    • LFB(France)
    • China Biologic Products Holdings, Inc.
    • Baxter
Product Code: FBI112839

Growth Factors of therapeutic albumin Market

The global therapeutic albumin market is witnessing steady growth due to the increasing prevalence of chronic diseases, trauma, and burn injuries. Therapeutic albumin, a purified protein derived primarily from human blood plasma, plays a crucial role in maintaining oncotic pressure, transporting hormones, enzymes, and drugs, and treating hypovolemia, burns, hypoalbuminemia, acute liver failure, and shock. The market's expansion is further supported by advancements in recombinant albumin production and increasing applications in regenerative medicine and cell therapy.

In 2025, the market was valued at USD 7.23 billion, growing to USD 7.70 billion in 2026, and projected to reach USD 13.33 billion by 2034, registering a CAGR of 7.10% from 2026-2034. Asia Pacific dominated in 2025 with a 55.49% share, driven by a high incidence of chronic diseases and burn cases.

Market Drivers and Trends

Increasing Chronic Disease Burden and Burn Incidents

The rising prevalence of liver disorders, kidney diseases, and cancer, along with increasing burn injuries, is driving market growth. For instance, the U.S. had 6.0 million kidney disease cases and 4.5 million chronic liver disease cases in 2024, while 32,540 severe burn cases required hospitalization in 2023, highlighting the significant demand for therapeutic albumin in fluid resuscitation and critical care settings.

Advancements in Albumin Production

Due to limitations of human-derived albumin, such as supply shortages, pathogen transmission risk, and batch variability, companies are investing in recombinant albumin and advanced albumin formulations. Innovations like Shilpa Medicare's sRbumin, a yeast-derived recombinant albumin, address supply gaps and improve safety and consistency.

Emerging Applications in Regenerative Medicine

Therapeutic albumin's biocompatibility and protein stabilization properties make it ideal for cell therapy and tissue engineering, presenting new opportunities for market growth. Collaborations, such as Albumedix and Heartseed, are exploring recombinant albumin in cardiac cell therapy, indicating expanding clinical applications.

Market Challenges

Regulatory hurdles, high production costs, and limited availability of human plasma remain key challenges. Approval processes from the FDA, EMA, and NMPA slow product launches, while developing economies struggle with accessibility and affordability. Supply chain disruptions, such as the 2024 U.S. blood shortage reported by the American Red Cross, further constrain market growth.

Market Segmentation

By Source

  • Human-derived albumin dominates with a 65.17% share in 2026, driven by chronic disease prevalence and robust product offerings from companies like Grifols, S.A., Octapharma AG, and Kedrion S.p.A.
  • Other sources, including recombinant or plant-derived albumin, are gaining traction to overcome supply constraints.

By Indication

  • Burns account for 89.66% of the market in 2026, due to fluid loss management in burn patients.
  • Hypovolemia is growing steadily due to conditions like extreme perspiration, diarrhea, or chronic heart and kidney disease.
  • Hypoalbuminemia and other indications exhibit moderate growth.

By Distribution Channel

  • Hospital pharmacies dominate (54.56% in 2026) due to inpatient treatments and surgical procedures.
  • Retail pharmacies provide widespread accessibility.
  • Online pharmacies are growing rapidly, fueled by digital adoption and home delivery convenience.

Regional Insights

Asia Pacific dominated in 2025 with USD 4.01 billion, projected to lead with Japan at USD 0.85 billion, China at USD 1.86 billion, and India at USD 0.46 billion in 2026, driven by chronic disease prevalence and burn cases.

North America is growing steadily, with the U.S. market projected at USD 1.52 billion in 2026, benefiting from strong plasma donation networks and advanced manufacturing facilities.

Europe holds the second-largest market, with the UK at USD 0.18 billion and Germany at USD 0.28 billion in 2026, supported by clinical trials and research activities.

Latin America and the Middle East & Africa hold smaller shares but are expected to grow due to rising chronic disease prevalence and increasing plasma collection initiatives.

Competitive Landscape

Key players like Grifols, S.A., Octapharma AG, Kedrion S.p.A., Takeda Pharmaceutical, CSL, and China Biologic dominate the market through strategic acquisitions, collaborations, and new product launches. Notable developments include Grifols inaugurating a new purification plant in Dublin (2022) and Shilpa Medicare completing FDA inspection of its facility in India (2025), highlighting the focus on production capacity expansion and regulatory compliance.

Conclusion

The therapeutic albumin market is projected to grow from USD 7.23 billion in 2025 to USD 13.33 billion by 2034, driven by chronic disease prevalence, burn injuries, technological advancements in recombinant albumin, and expanding clinical applications in regenerative medicine. Asia Pacific remains the leading region, while North America and Europe continue steady growth. Challenges like supply constraints, regulatory barriers, and high production costs persist, but innovations in recombinant albumin and advanced formulations are expected to sustain market growth and improve global patient access to this vital therapeutic protein.

Segmentation By Source

  • Human
  • Others

By Indication

  • Hypovolemia
  • Hypoalbuminemia
  • Burn
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region

  • North America (By Source, Indication, Distribution Channel, and Country)
    • U.S.
    • Canada
  • Europe (By Source, Indication, Distribution Channel, and Country/Sub-region)
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Source, Indication, Distribution Channel, and Country/Sub-region)
    • Japan
    • China
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Source, Indication, Distribution Channel, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Source, Indication, Distribution Channel, and Country/Sub-region)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Key Disorders: by Key Countries/Sub-regions, 2025
  • 4.2. Overview: rHSA Product Parameters
  • 4.3. New Product Launches, By Key Players
  • 4.4. Pipeline Analysis, By Key Players
  • 4.5. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
  • 4.6. Impact of COVID-19 on the Global Therapeutic Albumin Market

5. Global Therapeutic Albumin Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Source
    • 5.1.1. Human
    • 5.1.2. Others
  • 5.2. Market Analysis, Insights and Forecast - By Indication
    • 5.2.1. Hypovolemia
    • 5.2.2. Hypoalbuminemia
    • 5.2.3. Burn
    • 5.2.4. Others
  • 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.3.1. Hospital Pharmacies
    • 5.3.2. Retail Pharmacies
    • 5.3.3. Online Pharmacies
  • 5.4. Market Analysis, Insights and Forecast - Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Latin America
    • 5.4.5. Middle East & Africa

6. North America Therapeutic Albumin Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Source
    • 6.1.1. Human
    • 6.1.2. Others
  • 6.2. Market Analysis, Insights and Forecast - By Indication
    • 6.2.1. Hypovolemia
    • 6.2.2. Hypoalbuminemia
    • 6.2.3. Burn
    • 6.2.4. Others
  • 6.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.3.1. Hospital Pharmacies
    • 6.3.2. Retail Pharmacies
    • 6.3.3. Online Pharmacies
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
    • 6.4.2. Canada

7. Europe Therapeutic Albumin Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Source
    • 7.1.1. Human
    • 7.1.2. Others
  • 7.2. Market Analysis, Insights and Forecast - By Indication
    • 7.2.1. Hypovolemia
    • 7.2.2. Hypoalbuminemia
    • 7.2.3. Burn
    • 7.2.4. Others
  • 7.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.3.1. Hospital Pharmacies
    • 7.3.2. Retail Pharmacies
    • 7.3.3. Online Pharmacies
  • 7.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.4.1. Germany
    • 7.4.2. U.K.
    • 7.4.3. France
    • 7.4.4. Italy
    • 7.4.5. Spain
    • 7.4.6. Scandinavia
    • 7.4.7. Rest of Europe

8. Asia Pacific Therapeutic Albumin Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Source
    • 8.1.1. Human
    • 8.1.2. Others
  • 8.2. Market Analysis, Insights and Forecast - By Indication
    • 8.2.1. Hypovolemia
    • 8.2.2. Hypoalbuminemia
    • 8.2.3. Burn
    • 8.2.4. Others
  • 8.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.3.1. Hospital Pharmacies
    • 8.3.2. Retail Pharmacies
    • 8.3.3. Online Pharmacies
  • 8.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.4.1. China
    • 8.4.2. Japan
    • 8.4.3. India
    • 8.4.4. Australia
    • 8.4.5. Southeast Asia
    • 8.4.6. Rest of Asia Pacific

9. Latin America Therapeutic Albumin Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Source
    • 9.1.1. Human
    • 9.1.2. Others
  • 9.2. Market Analysis, Insights and Forecast - By Indication
    • 9.2.1. Hypovolemia
    • 9.2.2. Hypoalbuminemia
    • 9.2.3. Burn
    • 9.2.4. Others
  • 9.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.3.1. Hospital Pharmacies
    • 9.3.2. Retail Pharmacies
    • 9.3.3. Online Pharmacies
  • 9.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.4.1. Brazil
    • 9.4.2. Mexico
    • 9.4.3. Rest of Latin America

10. Middle East & Africa Therapeutic Albumin Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Source
    • 10.1.1. Human
    • 10.1.2. Others
  • 10.2. Market Analysis, Insights and Forecast - By Indication
    • 10.2.1. Hypovolemia
    • 10.2.2. Hypoalbuminemia
    • 10.2.3. Burn
    • 10.2.4. Others
  • 10.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.3.1. Hospital Pharmacies
    • 10.3.2. Retail Pharmacies
    • 10.3.3. Online Pharmacies
  • 10.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.4.1. GCC
    • 10.4.2. South Africa
    • 10.4.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. Takeda Pharmaceutical Company Limited.
      • 11.2.1.1. Overview
      • 11.2.1.2. Products
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. CSL
      • 11.2.2.1. Overview
      • 11.2.2.2. Products
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Grifols, S.A.
      • 11.2.3.1. Overview
      • 11.2.3.2. Products
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Octapharma AG
      • 11.2.4.1. Overview
      • 11.2.4.2. Products
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Kedrion S.p.A.
      • 11.2.5.1. Overview
      • 11.2.5.2. Products
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. Biotest AG
      • 11.2.6.1. Overview
      • 11.2.6.2. Products
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. LFB (France)
      • 11.2.7.1. Overview
      • 11.2.7.2. Products
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. China Biologic Products Holdings, Inc.
      • 11.2.8.1. Overview
      • 11.2.8.2. Products
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. Baxter
      • 11.2.9.1. Overview
      • 11.2.9.2. Products
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Therapeutic Albumin Market Revenue (USD billion) Forecast, by Source, 2021-2034
  • Table 2: Global Therapeutic Albumin Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 3: Global Therapeutic Albumin Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 4: Global Therapeutic Albumin Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 5: North America Therapeutic Albumin Market Revenue (USD billion) Forecast, by Source, 2021-2034
  • Table 6: North America Therapeutic Albumin Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 7: North America Therapeutic Albumin Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 8: North America Therapeutic Albumin Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 9: Europe Therapeutic Albumin Market Revenue (USD billion) Forecast, by Source, 2021-2034
  • Table 10: Europe Therapeutic Albumin Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 11: Europe Therapeutic Albumin Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 12: Europe Therapeutic Albumin Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 13: Asia Pacific Therapeutic Albumin Market Revenue (USD billion) Forecast, by Source, 2021-2034
  • Table 14: Asia Pacific Therapeutic Albumin Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 15: Asia Pacific Therapeutic Albumin Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 16: Asia Pacific Therapeutic Albumin Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 17: Latin America Therapeutic Albumin Market Revenue (USD billion) Forecast, by Source, 2021-2034
  • Table 18: Latin America Therapeutic Albumin Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 19: Latin America Therapeutic Albumin Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 20: Latin America Therapeutic Albumin Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 21: Middle East & Africa Therapeutic Albumin Market Revenue (USD billion) Forecast, by Source, 2021-2034
  • Table 22: Middle East & Africa Therapeutic Albumin Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 23: Middle East & Africa Therapeutic Albumin Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 24: Middle East & Africa Therapeutic Albumin Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Therapeutic Albumin Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Therapeutic Albumin Market Value Share (%), by Source, 2025 & 2034
  • Figure 3: Global Therapeutic Albumin Market Value Share (%), by Indication, 2025 & 2034
  • Figure 4: Global Therapeutic Albumin Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 5: Global Therapeutic Albumin Market Value Share (%), by Region, 2025 & 2034
  • Figure 6: North America Therapeutic Albumin Market Value (USD billion), by Source, 2025 & 2034
  • Figure 7: North America Therapeutic Albumin Market Value Share (%), by Source, 2025
  • Figure 8: North America Therapeutic Albumin Market Value (USD billion), by Indication, 2025 & 2034
  • Figure 9: North America Therapeutic Albumin Market Value Share (%), by Indication, 2025
  • Figure 10: North America Therapeutic Albumin Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 11: North America Therapeutic Albumin Market Value Share (%), by Distribution Channel, 2025
  • Figure 12: North America Therapeutic Albumin Market Value (USD billion), By Country, 2025 & 2034
  • Figure 13: North America Therapeutic Albumin Market Value Share (%), By Country, 2025
  • Figure 14: Europe Therapeutic Albumin Market Value (USD billion), by Source, 2025 & 2034
  • Figure 15: Europe Therapeutic Albumin Market Value Share (%), by Source, 2025
  • Figure 16: Europe Therapeutic Albumin Market Value (USD billion), by Indication, 2025 & 2034
  • Figure 17: Europe Therapeutic Albumin Market Value Share (%), by Indication, 2025
  • Figure 18: Europe Therapeutic Albumin Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 19: Europe Therapeutic Albumin Market Value Share (%), by Distribution Channel, 2025
  • Figure 20: Europe Therapeutic Albumin Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 21: Europe Therapeutic Albumin Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 22: Asia Pacific Therapeutic Albumin Market Value (USD billion), by Source, 2025 & 2034
  • Figure 23: Asia Pacific Therapeutic Albumin Market Value Share (%), by Source, 2025
  • Figure 24: Asia Pacific Therapeutic Albumin Market Value (USD billion), by Indication, 2025 & 2034
  • Figure 25: Asia Pacific Therapeutic Albumin Market Value Share (%), by Indication, 2025
  • Figure 26: Asia Pacific Therapeutic Albumin Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 27: Asia Pacific Therapeutic Albumin Market Value Share (%), by Distribution Channel, 2025
  • Figure 28: Asia Pacific Therapeutic Albumin Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 29: Asia Pacific Therapeutic Albumin Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 30: Latin America Therapeutic Albumin Market Value (USD billion), by Source, 2025 & 2034
  • Figure 31: Latin America Therapeutic Albumin Market Value Share (%), by Source, 2025
  • Figure 32: Latin America Therapeutic Albumin Market Value (USD billion), by Indication, 2025 & 2034
  • Figure 33: Latin America Therapeutic Albumin Market Value Share (%), by Indication, 2025
  • Figure 34: Latin America Therapeutic Albumin Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 35: Latin America Therapeutic Albumin Market Value Share (%), by Distribution Channel, 2025
  • Figure 36: Latin America Therapeutic Albumin Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 37: Latin America Therapeutic Albumin Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 38: Middle East & Africa Therapeutic Albumin Market Value (USD billion), by Source, 2025 & 2034
  • Figure 39: Middle East & Africa Therapeutic Albumin Market Value Share (%), by Source, 2025
  • Figure 40: Middle East & Africa Therapeutic Albumin Market Value (USD billion), by Indication, 2025 & 2034
  • Figure 41: Middle East & Africa Therapeutic Albumin Market Value Share (%), by Indication, 2025
  • Figure 42: Middle East & Africa Therapeutic Albumin Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 43: Middle East & Africa Therapeutic Albumin Market Value Share (%), by Distribution Channel, 2025
  • Figure 44: Middle East & Africa Therapeutic Albumin Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 45: Middle East & Africa Therapeutic Albumin Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 46: Global Therapeutic Albumin Market Share (%), By Company, 2025